atherosclerotic cardiovascular disease with elevated triglycerides
Cardiovascular · 2023–2024
2decisions
1medicine
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| icosapent ethyl Treatment of patients with established atherosclerotic cardiovascular disease (ASCVD) and elevated triglycerides (fasting triglyceride level between 1.7 mmol/L… | Mar 2024 | Recommended with restriction | input received |
| icosapent ethyl Treatment of patients with atherosclerotic cardiovascular disease (ASCVD) and elevated triglycerides (≥1.7 mmol/L and <5.6 mmol/L) with LDL cholesterol between… | Nov 2023 | Not recommended | input received |
What the PBS pays
$1M in government benefit over 2024–25, across 5,258 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| icosapent ethyl | $0.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.